Sneak Peek Inside the CSU Treatment Pipeline
Jason Hawkes, MD, MS, a dermatologist in Rocklin, CA, reviews currently available and emerging treatments for chronic spontaneous urticaria (CSU), including dupilumab (Dupixent, Sanofi, and Regeneron Pharmaceuticals), remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase (BTK) inhibitor, other BTK inhibitors, interleukin 5 (IL-5) inhibitors and C-kit blockers.